KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriertAktuelle implizite Wahrscheinlichkeit
Ja 98%
Marktqualitat
45 / 100
Niedrige Qualität24h-Volumen
644,8 €
Liquidität
1930,6 €
Niedrige LiquiditätGeld / Brief
77.0% / 99.0%
Spread
22.0 pt
Breiter SpreadMarktdaten
Aktualisiert vor 4 Minuten
17. Juni 26, 21:00 UTC1. Jan. 27, 04:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiFDA decision: Venglustat by Sanofi (in 2026)
KalshiFDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRegeln
If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Abwicklung über:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Bepirovirsen is an experimental antiviral medicine developed by GlaxoSmithKline that is designed to clear the hepatitis B virus from the body rather than just keeping it asleep.
- It belongs to a modern class of gene-silencing therapies that hunt down and destroy the virus's replication instructions.
- This is similar to intercepting and shredding a virus’s blueprints before its cell-invading factory has a chance to read them and build new viral copies.
Offene Märkte
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Gesamtvolumen
- 15,6 Mio. €
- 24h-Volumen
- 18.288,2 €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Gesamtvolumen
- 1,6 Mio. €
- 24h-Volumen
- 5178,9 €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 weitere Ergebnisse
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Gesamtvolumen
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Gesamtvolumen
- 916.002,6 €
- 24h-Volumen
- 1515,1 €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 weitere Ergebnisse
- Gesamtvolumen
- 863.640,2 €
- 24h-Volumen
- 1039 €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Häufige Fragen
- Wie stehen die aktuellen Quoten für FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)?
- Kalshi bewertet Yes mit 98% (Stand: 8. September 2026).
- Wann wird FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) entschieden?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) soll am 1. Januar 2027 entschieden werden.
- Wie wird FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) abgerechnet?
- Kalshi rechnet diesen Markt wie folgt ab: If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.